Table 2. Baseline characteristics and demographic features of the study population (n = 57).
| Total (n = 57) | Recurrence (–) (n = 50) | Recurrence (+) (n = 7) | p-value | |
| Failed anti-arrhythmics (n) | ||||
| Amiodarone | 13 | 11 | 2 | 0.630 |
| Propofenone | 27 | 23 | 4 | 0.594 |
| βb or CKB | 17 | 15 | 2 | 0.409 |
| Age, years (mean ± SD) | 55.1 ± 12.13 | 54 ± 1 | 65 ± 15 | 0.021 |
| Gender, female, n (%) | 29 (50) | 26 (52) | 3 (42) | 0.658 |
| BMI, kg/m2 | 24.8 ± 3.7 | 24.8 ± 3.6 | 24.7 ± 3.7 | 0.126 |
| Diabetes mellitus, n (%) | 10 (17) | 9 (18) | 1 (14) | 0.195 |
| Hypertension, n (%) | 25 (43) | 21 (42) | 4 (57) | 0.451 |
| CAD, n (%) | 9 (15) | 8 (16) | 1 (14) | 0.457 |
| Smoking, n (%) | 28 (49) | 25 (50) | 3 (42) | 0.702 |
| Duration of AF history, years | 3.9 ± 2.6 | 3.5 ± 2.5 | 6.7 ± 4.5 | 0.002 |
| LA diameter, mm | 41.32 ± 4.51 | 40.72 ± 4.16 | 46.23 ± 4.36 | 0.002 |
| LVEF, % | 59.23 ± 5.12 | 59.48 ± 4.78 | 56.42 ± 5.56 | 0.146 |
| CHA2DS2-VASc score, mean ± SD | 1.3 ± 1.17 | 1.3 ± 1.11 | 1.7 ± 1.60 | 0.414 |
| EHRA score, mean ± SD | 2.45 ± 0.56 | 2.44 ± 0.54 | 2.57 ± 0.78 | 0.573 |
| Follow-up time, days, mean ± SD | 214 ± 24 | 212 ± 23 | 213 ± 25 | 0.117 |
AF, atrial fibrillation; βb, beta-blocker; BMI, body mass index; CKB, Ca channel blocker; CAD, coronary artery disease; EHRA, European Heart Rhythm Association; LA, left atrium; LVEF, left ventricular ejection fraction; SD, standard deviation, p < 0.05.